Category Archives: Solid organ

Low Grade Spleen Injury With Contrast Blush

December 10, 2024 The Trauma Pro Leave a comment

It is almost a given that low-grade solid organ injuries are relatively benign and seldom require any intervention. In fact, some trauma centers actually discharge these patients home from the emergency department.

But what about low-grade isolated spleen injuries with a contrast blush? Apparently, a few authors believe that this may be a benign condition that doesn’t require any specific management. This didn’t sit well with some, and a multicenter study was launched to look at this group more closely.

A retrospective cohort study involving 21 trauma centers was organized via the Eastern Association for the Surgery of Trauma. It enrolled adults (>18 years) with a grade I or II injury on CT scan after blunt trauma, which also demonstrated a contrast blush. Hemodynamically unstable patients and those who had clotting disorders or were taking any anticoagulant other than aspirin were excluded.

Here are the factoids:

Although 209 patients were enrolled over a nearly six-year period, 64 were removed due to meeting exclusion criteria or undergoing some intervention or laparotomy for other injuries
The remaining 145 patients were 66% men with an average age of 47
About one-third had a grade I injury, and two-thirds had grade II
20% of these patients failed nonoperative management
These results were unchanged between grade I (18%) and grade II (21%)
Those who failed had a longer hospital stay (8 days vs. 5 days), had a higher likelihood of blood transfusion (55% vs. 26%) and MTP activation (14% vs. 3%)
There was no difference in discharge disposition or mortality

Bottom line: This study was conducted between 2014 and 2019. During that period, the AAST spleen and liver injury grading scales did not consider vascular injury. The 2018 update automatically upgrades injuries with blush or extravasation to Grade IV. This has a significant impact on how we view these injuries.

I have always said that any patient with contrast extravasation is bleeding to death until we stop it. The only exception is pediatric patients, who seem to clot these on their own. The 2018 update bore this out, and this paper confirms that low-grade anatomic injuries become dangerous if extravasation is present. I would also extend this to patients with a CT showing significant pseudoaneurysm formation.

So what should you do? If you have a patient with a spleen or liver injury that has contrast extravasation or a pseudoaneurysm, consider this a patient that needs hemorrhage control by interventional radiology under Standard 4.15 in the 2022 ACS Resources for Optimal Care of the Injured Patient. This means that you must let your IR team know that you have a patient who needs an intervention within 60 minutes, or you will need to transfer to a center with those capabilities as soon as possible.

Reference: Failure rates of nonoperative management of low-grade splenic injuries with active extravasation: an Eastern Association for the Surgery of Trauma multicenter study. Trauma Surg Acute Care Open. 2024 Mar 7;9(1):e001159. doi: 10.1136/tsaco-2023-001159. PMID: 38464553; PMCID: PMC10921525.

Abdomen, Solid organ

Use Of A Solid Organ Injury Protocol For Pediatrics

February 23, 2024 The Trauma Pro Leave a comment

Kids are frequent flyers when it comes to abdominal injury, with about 15% of their injuries involving this anatomic area. Solid organ injuries, mainly the liver and spleen, are the most prevalent ones. The American Pediatric Surgical Association (APSA) published a practice guideline way back in 2000 that outlined a consistent way to care for children with solid organ injuries.

Unfortunately, they were very conservative, recommending days of bedrest, extended NPO status, very frequent blood draws, and a lengthy hospital stay. Many hospitals, including mine, developed less conservative management routines, noting that children nearly always tolerate liver and spleen injury better than adults.

The trauma group at Vanderbilt modified the APSA guidelines and, more recently, made additional changes based on a new algorithm released by the organization. This new guideline moved away from organ injury grade-based factors and embraced hemodynamic status as the overall guide to care. The Vanderbilt group performed a retrospective study comparing hospital and ICU length of stay, patient costs, readmission, and death rates using the two guidelines.

Under the old protocol, grade I-III injuries were admitted to a floor bed and higher grades to an ICU at the discretion of the surgeon. The minimum hospital stay was, at minimum, the organ injury grade. Children were kept NPO overnight and placed on bed rest for nearly one day per injury grade.

With the new protocol, children were admitted to the floor if their vital signs normalized after volume resuscitation. Hematocrit was obtained on admission and possibly again after 6 hours, then only repeated if < 21 or a change in vitals was noted. There were no diet or activity restrictions. Children with abnormal vital signs after volume were admitted to the ICU and kept on bed rest until they normalized. Labs were drawn regularly. Length of stay was based on meeting pain control, diet, and activity goals.

Here are the factoids:

There were 176 children (age < 18) enrolled in the old protocol during a four-year period and 170 in the new protocol over 3.5 years
Both groups were similar demographically and in injury grade and ISS
ICU length of stay was “significantly” shorter under the new protocol (.54 vs .78 days)
Hospital length of stay was also “significantly” shorter (2.9 vs 3.5 days)
Inflation-adjusted costs were slightly higher under the new protocol ($68,042 vs $65,437) even though the authors claim the opposite in the abstract once injury grade and ISS are factored in
Survival was the same at 99.4%
Readmission rates were significantly higher under the new protocol (7.1% vs 2.3%)

The authors’ conclusions parroted these results and recommended larger studies to detail any cost advantage and identify the cause for the difference in readmission rates.

Bottom line: This study leaves a lot to be desired. The authors’ definition of “pediatric” is age < 18. As we all know, there is a big difference in “kids” who are pre- vs post-puberty. The good news is that the mean and median ages are about 11 in the study, so there should be fewer older “kids” to cause interference.

The authors reported hazard ratios for the lengths of stay, which were statistically significantly different. However, their clinical significance is in doubt. A difference of 6 ICU hours? Or two-thirds of a hospital day? I’m not impressed.

Cost differences are basically a wash, and a deep read of the paper shows that many kids did not have an isolated solid organ injury. Non-abdominal injuries could have an Abbreviated Injury Scale score of up to 3. It is easy to imagine that these could impact both length of stay and cost.

Finally, the readmission rates include many problems related to non-abdominal injuries, including the thorax, soft tissues, and even an epidural hematoma. After excluding these non-abdominal complications, the numbers for both protocols are so low it’s hard to believe that a good significance test can be performed.

The authors’ conclusions are correct: more work needs to be done. This paper doesn’t really teach us much since all the conclusions are extremely weak. A much better, prospective, multicenter trial should be performed. Unfortunately, getting buy-in from multiple centers/surgeons to use the same protocol in children is hard.

But with all that being said, there is no reason you can’t adopt something similar to the new protocol at your center. My own experience has shown that a more aggressive guideline gets kids home sooner and healthier and that there is no difference in readmission rates. I just need a bunch of other surgeons to duplicate these results and write them up!

Reference: A Protocol Driven Approach to Reduce Lengths of Stay for Pediatric Blunt Liver and Spleen Injury Patients. Journal of Trauma and Acute Care Surgery ():10.1097/TA.0000000000004259, January 26, 2024. | DOI: 10.1097/TA.0000000000004259

Practice guidelines, Solid organ

New EAST Practice Guideline: Spleen Vaccines After Angioembolization

August 25, 2023 The Trauma Pro Leave a comment

I am trying to figure out how I missed it! The Eastern Association for the Surgery of Trauma (EAST) snuck a new practice management guideline into the Injury journal last fall. And it desperately tries to answer a question that has been hanging around for several years. Do we vaccinate spleen injury patients who undergo angioembolization or not?

I’ve been pondering this for some time and have reached my own conclusion based on some very old literature. Decades ago, we figured out that removing the spleen significantly affects immune function. Splenectomy patients are known to be more susceptible to encapsulated bacteria like Neisseria meningiditis, Streptococcus pneumoniae, and Haemophilus influenzae. Most trauma centers routinely vaccinate these patients before they are discharged home.

With the more recent emphasis on splenic salvage and nonoperative management of injury to this organ, angioembolization has become commonplace. This technique can be done in two ways: proximal and distal. Proximal embolization blocks the splenic artery, so there is no further blood flow to the spleen through it. Distal embolization (selective or super-selective) strives to block flow to very specific areas of the organ.

Do we need to give the vaccines if we cut off blood flow to pieces of the spleen or the main splenic artery? Based on my appreciation of very old splenectomy and partial splenectomy papers, it looked like we should in some cases. One report showed that splenic protection from encapsulated bacteria required about 50% of the spleen to be present and perfused by the splenic artery. This caveat stems from a time when we would perform a trauma splenectomy, dice the spleen up on the back table, and then implant a bunch of spleen cubes into the mesentery to try to provide some immune protection. Turns out that the pieces lived but didn’t do a damn thing.

My practice, then, has been to look at the fluoro images and estimate how much of the spleen was left. I would order the vaccines if a main splenic artery embolization (proximal) was performed. If a distal embolization were performed, I would eyeball the amount of devascularized spleen and give the vaccines if it looked like more than half was dark. Not very precise, I know.

But what would EAST say? They tried to perform a systematic review and meta-analysis of studies that compared outcomes in splenectomy vs. angioembolization patients. Unfortunately, there isn’t a lot of research material out there. So they settled on looking at papers that analyzed immune function, typically using B-cells, T-cells, and antibodies. The authors performed two comparisons: angioembolization vs. splenectomy and angioembolization vs. control.

Angioembolization vs. Splenectomy

These papers compared embolization patients who may or may not have spleen function to splenectomy patients who definitely have none. Embolization patients had fewer infectious complications during their hospital stay and better immune function using the indirect methods noted above. Unfortunately, the data quality was poor, with a significant risk of bias. There was no stratification of proximal vs. distal embolization. Nevertheless, this suggests that, at least overall, the embolization patients retained immune function.

Angioembolization vs. Controls

What about comparing embolization patients to spleen-injured patients who did not undergo any procedure? They should have normal function. Again, the quality of the very few papers available was low. But overall, there was no difference in immune function between the groups.

Bottom line: The EAST review team conditionally recommended against routine spleen vaccines after angioembolization for spleen injury. They concluded that immune function was maintained, so it should not be necessary.

What, you ask, about patients with proximal splenic embolization? The reality is that this only stops inflow from the splenic artery, and only for a few days or weeks. It may slowly resume over time. And it does nothing to the inflow from the short gastric arteries. Apparently, this is enough to provide immune protection against infection.

Whether this is actually true is open to debate. We have no idea if the numbers of T- and B-cells seen and the antibody titers are actually enough to avoid overwhelming post-splenectomy sepsis. And unfortunately, this condition is so rare that we will never accumulate enough cases to make a definitive statement.

But for now, it is probably okay to forgo the vaccines in patients undergoing angioembolization. Besides, the differing guidelines on which vaccines to use, when to give them, and when to schedule boosters were getting way out of hand! Please keep it simple!

Reference: Vaccination after spleen embolization: a practice management guideline from the Eastern Association for the Surgery of Trauma. Injury 53:3569-3574, 2022.

Solid organ

The End Of Serial Hemoglobin/Hematocrit In Solid Organ Injury

May 26, 2023 The Trauma Pro Leave a comment

Here’s the final post on my series covering serial hemoglobin testing in the management of solid organ injury.

We developed our first iteration of a solid organ injury practice guideline at Regions Hospital way back in 2002. It was borne out of the enormous degree of clinical variability I saw among my partners. We based it on what little was publicly available, including an EAST practice guideline.

Recognizing that the EAST guideline couldn’t dictate bedside care, we gathered together to meld it with our own clinical experience. We fashioned our first practice guideline later that year and tested it. It included instructions for bedrest (only overnight), vital signs monitoring, and lab testing (on admission and once the next day).

That last bit about serial lab tests is an important one. We had seen anecdotal evidence in our patients that it wasn’t very helpful. For example, I had one patient in the ICU whose serial Hgb had just returned normal. However, a minute later they experienced a hard hypotensive episode, and I took him immediately to the OR and took out a ruptured and bleeding spleen.

I’ve written several posts on how quickly Hgb changes after hemorrhage. Unfortunately, this lab test just lags too long to be a reliable indicator of anything. A very recent study has been published by Texas Health Presbyterian in Dallas. The retrospectively reviewed patients with liver or spleen injury over five years. They examined how often serial hemoglobin determinations influenced management during the study period. Possible interventions were none, operation, angioembolization, or blood transfusion.

Here are the factoids:

There were 143 patients enrolled, and half had no interventions, a third had interventions within 4 hours, and the remainder (16%) had an intervention after 4 hours
In the early intervention group, one-third underwent laparotomy, 42% angiography, and 9% had both; 17% received transfusions based on clinical parameters alone and not lab results
Of the 16% that did have a later intervention (23 patients), 12 received a blood transfusion only based on a Hemoglobin value, and all but one had no further interventions. That patient had a laparotomy based on the lab test.
All other patients in the late intervention group went to OR or angioembolization based on hemodynamics or a change in physical exam.
The number of blood draws was phenomenal, with an average of 19 in the early intervention group, 17 in the delayed intervention group, and 7 in the no-intervention group

The authors concluded that serial hemoglobin measurements were not well-supported by the literature and that the decision for intervention was nearly always driven by hemodynamics or physical exam.

Bottom line: Although this study is small, the results are very clear. As we were taught in our surgical training, hemodynamics and physical exam are vital in managing solid organ injury. Unfortunately, hemoglobin is a lagging indicator, and the repeated discomfort and unnecessary cost overshadow its clinical value. This is most significant when treating pediatric patients.

Try to recall the last time you and your trauma colleagues had a patient whose need for intervention was based on a lab draw. Now take your practice guideline back to the drawing board and eliminate the serial exams!

Click here for an example of a serial Hgb-free solid organ injury practice guideline

Reference: Role of Serial Phlebotomy in the Management of Blunt
Solid Organ Injury in Adults. J Trauma Nurs 30(3), 135–141, 2023.

Abstracts, Pharmacy, Solid organ

Best Of EAST 2023 #10: Early VTE Prophylaxis In Adolescents With Solid Organ Injury

January 17, 2023 The Trauma Pro Leave a comment

Chemoprophylaxis against venous thromboembolism (VTE) is routine in trauma care. In most cases, it can be initiated shortly after admission in most trauma patients. However, there are a few major exceptions, including eye injuries and brain injuries with intracranial hemorrhage.

Solid organ injury used to be cause for concern when considering prophylaxis, but most trauma centers are now comfortable beginning within 24 to 48 hours after injury. Having said that, those numbers are for adult patients. What about the younger ones?

The University of California Irvine group queried the TQIP database (3 recent years) to examine outcomes for adolescent patients (12-17 years old) given VTE prophylaxis after injury to liver, spleen, and/or kidney. They excluded patients who had TBI, anticoagulation or coagulopathy, immediate laparotomy, transfers in, and patients who died or were discharged within 48 hours. They matched patients for age, comorbidities, grade of injury, overall severity of injury, and hypotension/need for transfusion.

Eligible patients who received chemoprophylaxis early (within 48 hours) vs. late were reviewed to identify any differences in complications, length of stay, failed non-op management, and mortality.

Here are the factoids:

A total of 1,022 cases were isolated from the TQIP database, and 417 adolescent cases were matched to adults
VTE rate was statistically the same, 0.6% in the early group vs. 1.7% in the delayed group
Failed non-op management was identical at 5.9% vs. 5.6%
There was one death in the delayed group and none in the early group (not significant)
ICU LOS was the same at 3-4 days
One item not mentioned in the body of the abstract: hospital length of stay was significantly longer in the early group: 9 days vs. 6 days

The authors concluded that early VTE prophylaxis in adolescent trauma patients did not increase failure of nonoperative management, nor did it decrease the incidence of VTE.

Bottom line: This is a study that needed to be done. Due to IRB restrictions, it is typically more challenging to perform actual studies on children and adolescents. Retrospective use of databases helps overcome this problem, although it always introduces a few unwanted wrinkles.

We frequently assume that adolescents behave physiologically like adults. Although often true, you can’t always count on it. Those of us who take care of children and young adults know that they tend to do better than adults by most measures. But again, this is an assumption and needed to be studied.

This database study was limited to three years of data and only produced 417 matched cases for study. This is a small number, and I always worry about statistical power. If the results of such a study are negative, one is left wondering if a proper power analysis was done.

One puzzling result left me wondering about the power question. Patients who received early prophylaxis had exactly the same rate of VTE as those who received it late. Adult data indicates that early use should decrease this complication. Is this another indication of a statistical power problem? Would the inclusion of more patients have shown a real difference?

The other result that struck me (and was not commented upon in the body of the abstract) was the statistically significant 50% increase in hospital length of stay for the early prophylaxis group. Is there some unknown variable that was not matched that caused it? This is one of the known pitfalls of these retrospective database studies.

Here are my questions and comments for the presenter/authors:

Broken record question: Did you have enough cases to provide adequate statistical power? This study showed a negative result. Did you have enough matched cases to actually be able to detect a difference if there was one? Why not add a few more years of data and recalculate?
How do you explain the failure of early VTE prophylaxis to protect these patients from DVT or PE? Is this also a statistical power problem?
Why is the hospital length of stay significantly longer in the early prophylaxis group?

This intriguing paper follows my bias toward treating these patients exactly the same as adults with early chemoprophylaxis. I just need a few of the loose ends tied up.

Reference: SIMILAR RATE OF VENOUS THROMBOEMBOLISM AND FAILURE OF NON-OPERATIVE MANAGEMENT FOR EARLY VERSUS DELAYED VTE CHEMOPROPHYLAXIS IN ADOLESCENT BLUNT SOLID ORGAN INJURIES: A PROPENSITY-MATCHED ANALYSIS. EAST 2023 Podium paper #27.

Home of the Trauma Professional's Blog